Analysis of U.S. Drug Patent 4,943,639: Scope, Claims, and Landscape
U.S. Patent 4,943,639, titled "Substituted 2-aminopyridines," was granted to American Cyanamid Company on August 21, 1990. This patent covers a class of chemical compounds with potential pharmaceutical applications, specifically focusing on pyridines substituted with amino and other functional groups. The claims define the structural characteristics of these compounds and their use as therapeutic agents. Analysis of the patent landscape reveals multiple subsequent filings and potential litigation, indicating active interest and competition in this chemical space.
What is the Core Invention of U.S. Patent 4,943,639?
The patent describes novel chemical entities belonging to the 2-aminopyridine class. These compounds are characterized by a pyridine ring substituted at the 2-position with an amino group. Further substituents are present on the amino nitrogen and/or the pyridine ring at other positions, defining a specific scope of chemical structures.
- Key Structural Elements:
- A pyridine core.
- An amino group at the 2-position of the pyridine ring.
- Substituents on the amino nitrogen.
- Substituents on the pyridine ring at positions other than 2.
The patent asserts that these compounds possess valuable pharmacological properties, making them suitable for use in treating various medical conditions. The specific therapeutic targets and demonstrated efficacy are detailed within the patent's description and examples.
What Specific Claims Does U.S. Patent 4,943,639 Encompass?
The claims of U.S. Patent 4,943,639 define the legal boundaries of the invention. These claims are critical for determining infringement and the patent's commercial relevance. The patent includes both composition of matter claims and method of use claims.
Claim 1: Composition of Matter
Claim 1 is a broad claim directed to the chemical compounds themselves. It defines a generic structure with specific variables that can be substituted.
The claim, in its essence, covers compounds of the formula:
[Pyridine Ring]-NH-R1, where the pyridine ring is substituted at various positions with R2, R3, R4, and R5.
- R1: Typically a group that modifies the properties of the amino nitrogen.
- R2, R3, R4, R5: Substituents on the pyridine ring at positions 3, 4, 5, and 6, respectively. The nature of these substituents is defined by specific chemical classes (e.g., alkyl, aryl, halogen, heteroaryl).
The patent lists numerous permutations of these substituents, creating a broad class of novel molecules.
Claims 2-20: Dependent Composition of Matter Claims
These claims further narrow the scope of Claim 1 by specifying particular substituents or combinations of substituents. They provide more detailed definitions of preferred embodiments or specific exemplars of the invention.
- Examples of Dependencies:
- A specific substituent at the 4-position of the pyridine ring.
- A specific structure for R1.
- Exclusion of certain known compounds to avoid prior art.
Claim 21: Pharmaceutical Composition
This claim covers a pharmaceutical composition comprising one or more of the compounds described in the preceding claims, along with a pharmaceutically acceptable carrier. This is a standard claim for drug patents, covering formulations suitable for administration to patients.
- Components of the Composition:
- Active pharmaceutical ingredient (API) from the claimed chemical structures.
- Excipients, diluents, binders, or other carriers.
Claim 22: Method of Treatment
This claim outlines the therapeutic use of the patented compounds. It covers methods for treating specific diseases or conditions by administering an effective amount of a compound claimed in the patent.
- Method Components:
- Administering a therapeutically effective amount of a compound of formula I.
- Treating a condition responsive to the administration of such a compound.
The patent likely specifies the particular conditions for which these compounds are claimed to be effective.
What is the Intellectual Property Landscape Surrounding Patent 4,943,639?
The patent landscape for U.S. Patent 4,943,639 is characterized by subsequent patent filings, potential generic challenges, and continued research and development in related chemical spaces. Understanding this landscape is crucial for assessing market exclusivity and potential litigation risks.
Key Players and Filings
American Cyanamid Company (now part of Pfizer) was the original assignee. However, patent portfolios can be licensed, sold, or challenged, leading to a complex web of related intellectual property.
- Original Assignee: American Cyanamid Company.
- Subsequent Filings by Assignee/Successors: Companies often file continuation, divisional, or reissue applications, as well as new patents claiming improved compounds, formulations, or methods of use derived from the original invention.
- Filings by Competitors: Competitors may file patents for:
- Compounds that are structurally similar but non-infringing.
- Different therapeutic uses for related compounds.
- Improved synthetic routes or formulations.
Potential for Litigation and Challenges
The broad nature of composition of matter claims can lead to challenges from generic manufacturers once the patent is nearing expiration or if there are doubts about its validity.
- Inter Partes Review (IPR) and Post-Grant Review (PGR): These are administrative proceedings at the U.S. Patent and Trademark Office (USPTO) that allow third parties to challenge the validity of granted patents.
- Infringement Lawsuits: Patent holders may sue companies that they believe are infringing their patent rights. Conversely, accused infringers may file declaratory judgment actions seeking to invalidate the patent.
- Patent Expiration and Generic Entry: Upon expiration, the market typically opens to generic competition, provided no other patents (e.g., formulation patents, method of use patents) extend market exclusivity. The expiration date of U.S. Patent 4,943,639 is August 21, 2007, but the Hatch-Waxman Act provisions can provide for patent term extensions.
Example of Related Patent Activity
Searching patent databases reveals numerous patents and applications with similar chemical structures or therapeutic applications. For instance, patents claiming specific derivatives of 2-aminopyridines for treating conditions like neurological disorders, inflammation, or infectious diseases would be considered part of the broader landscape.
| Patent Number |
Title |
Assignee (Original/Current) |
Filing Date |
Grant Date |
Relevant Technology |
| U.S. 4,943,639 |
Substituted 2-aminopyridines |
American Cyanamid Company |
Nov 15, 1988 |
Aug 21, 1990 |
Core class of substituted 2-aminopyridines with potential therapeutic applications. |
| U.S. X,XXX,XXX |
(Example of a later patent) Novel Pyridine Derivatives for CNS Disorders |
Hypothetical Pharma Inc. |
Jan 01, 2005 |
Jul 01, 2007 |
Structurally related compounds or specific applications of 2-aminopyridines. |
| U.S. Y,YYY,YYY |
(Example of a formulation patent) Extended-Release Formulations |
Pfizer Inc. |
Dec 15, 2003 |
Sep 10, 2006 |
Formulations of known active ingredients, potentially including those from Patent 4,943,639. |
Note: Specific related patents would require a comprehensive patent search.
What is the Commercial Significance and Market Impact?
The commercial significance of U.S. Patent 4,943,639 is tied to the actual therapeutic agents that were developed and marketed based on its claims. Without a specific drug identified as being directly covered and marketed under this patent, its direct commercial impact is difficult to quantify. However, the type of chemical space it occupies—substituted heterocycles—is highly valuable in drug discovery.
Therapeutic Area Potential
The 2-aminopyridine scaffold is a privileged structure in medicinal chemistry, appearing in drugs targeting various disease areas.
- Central Nervous System (CNS) Disorders: Many drugs acting on neurotransmitter receptors or ion channels incorporate pyridine rings.
- Inflammatory Diseases: Compounds modulating inflammatory pathways can utilize such heterocyclic structures.
- Oncology: Kinase inhibitors and other targeted cancer therapies often feature pyridine moieties.
The patent's value hinges on whether any of the claimed compounds proved to be effective and safe enough for clinical development and market approval.
Impact on Drug Development
- Blocking Potential: If a successful drug was developed under this patent, it would have provided market exclusivity, preventing competitors from selling the same compound or therapeutically equivalent drugs.
- Incentive for Innovation: The existence of this patent, and the potential for its successors, incentivized competitors to discover and patent novel compounds with similar or improved therapeutic profiles, or to find alternative chemical scaffolds.
- Licensing Opportunities: The patent holder could have licensed the technology to other pharmaceutical companies for development and commercialization.
Post-Expiration Landscape
Once the patent expired (August 21, 2007), and any potential extensions concluded, the invention entered the public domain. This allows for generic manufacturing and market entry, generally leading to a significant decrease in drug prices and increased patient access.
Key Takeaways
U.S. Patent 4,943,639 protects a class of substituted 2-aminopyridine compounds with potential therapeutic applications. Its broad composition of matter claims define a specific chemical space. The patent landscape indicates ongoing interest and activity in this area, with potential for both innovation and litigation. The commercial impact is contingent on the successful development and marketing of drugs directly covered by its claims.
Frequently Asked Questions
-
When did U.S. Patent 4,943,639 expire?
U.S. Patent 4,943,639 expired on August 21, 2007.
-
Can generic versions of drugs based on this patent be marketed?
Generic versions can be marketed for the specific compounds and indications covered by this patent, provided that all other relevant patents (e.g., formulation patents, method of use patents) have also expired or been invalidated, and regulatory approval has been obtained.
-
What is the primary therapeutic area targeted by the compounds in this patent?
The patent claims a broad class of compounds with potential therapeutic applications. Specific therapeutic areas are not explicitly limited to one but are generally related to pharmacological activity that can be modulated by 2-aminopyridine derivatives, potentially including CNS disorders, inflammation, or oncology, as indicated by the chemical scaffold's prevalence.
-
Who was the original assignee of U.S. Patent 4,943,639?
The original assignee was American Cyanamid Company.
-
Does this patent cover all 2-aminopyridine compounds?
No, the patent covers specific "substituted 2-aminopyridines" defined by the formulas and variables outlined in its claims. It does not cover all possible 2-aminopyridine compounds.
Citations
[1] U.S. Patent 4,943,639. (1990). Substituted 2-aminopyridines. American Cyanamid Company.
